| BEAM |
Beam Therapeutics Inc. |
72%
|
Reciprocal relationship from BEAM graph: Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions… |
| BEAM |
Beam Therapeutics Inc. |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| GRFS |
Grifols, S.A. |
72%
|
Reciprocal relationship from GRFS graph: Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions… |
| GRFS |
Grifols, S.A. |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| KRRO |
Korro Bio, Inc. |
72%
|
Reciprocal relationship from KRRO graph: Reciprocal relationship from MREO graph: Reciprocal relationship from KRRO graph: Reciprocal relationship from MREO graph: Reciprocal relationship from KRRO g… |
| KRRO |
Korro Bio, Inc. |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| KRYS |
Krystal Biotech, Inc. |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| KRYS |
Krystal Biotech, Inc. |
72%
|
Reciprocal relationship from KRYS graph: Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions… |
| LLY |
Eli Lilly and Company |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| LLY |
Eli Lilly and Company |
72%
|
Reciprocal relationship from LLY graph: Reciprocal relationship from MREO graph: Reciprocal relationship from LLY graph: Reciprocal relationship from MREO graph: Reciprocal relationship from LLY grap… |
| NVSEF |
Novartis AG |
72%
|
million, compared to a loss of $1.4 million in the year ended December 31, 2024. This change primarily reflects the impact of a weakening in the value of U.S. dollars when translating pound sterling … |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from MREO graph: million, compared to a loss of $1… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from MREO graph: data that is stored on their systems. Any loss of clinical trial data from our completed or ongoing clinical trials … |
| SNYNF |
Sanofi |
72%
|
data that is stored on their systems. Any loss of clinical trial data from our completed or ongoing clinical trials for any of our product candidates could result in delays in our development and reg… |
| WVE |
Wave Life Sciences Ltd. |
72%
|
Reciprocal relationship from WVE graph: Reciprocal relationship from MREO graph: o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions … |
| WVE |
Wave Life Sciences Ltd. |
72%
|
o BioPharma 5, (formerly OncoMed) under the CVR Agreement of a total of $0.9 million (£0.7 million), after deductions of costs, charges and expenditures. In the fourth quarter of 2023, Feng Bioscienc… |
| AZN |
AstraZeneca PLC |
70%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from MREO graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MREO graph: under various agreements with Novarti… |
| AZN |
AstraZeneca PLC |
70%
|
under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on potential future commercial sales |
| NVS |
Novartis AG |
70%
|
Reciprocal relationship from NVS graph: Reciprocal relationship from MREO graph: Reciprocal relationship from NVS graph: Reciprocal relationship from MREO graph: under various agreements with Novarti… |
| NVS |
Novartis AG |
70%
|
under various agreements with Novartis and AstraZeneca, we have agreed to make milestone payments and pay royalties on potential future commercial sales |
| FENG-BIOSCIENCES-INC |
FENG-BIOSCIENCES-INC |
62%
|
6 million in the three months ended March 31, 2025. This change primarily reflects the impact of a strengthening in the value of U.S. dollars when translating pound sterling functional currency balan… |
| ONCXERNA-THERAPEUTICS-INC |
ONCXERNA-THERAPEUTICS-INC |
62%
|
6 million in the three months ended March 31, 2025. This change primarily reflects the impact of a strengthening in the value of U.S. dollars when translating pound sterling functional currency balan… |
| SISAF-LTD |
SISAF-LTD |
62%
|
data that is stored on their systems. Any loss of clinical trial data from our completed or ongoing clinical trials for any of our product candidates could result in delays in our development and reg… |
| U-K-THE-GROUP |
U-K-THE-GROUP |
62%
|
esulting amounts allocated to each performance obligation are consistent with the amounts the Company would expect to receive for each performance obligation. The Company then recognizes as revenue t… |
